Select Page

Breast Cancer FDA Approval Updates

Neratinib for extended adjuvant treatment of early stage HER2-positive breast cancer Neratinib is approved by the U.S. Food and Drug Administration for extended adjuvant treatment of early stage HER2-overexpressed/amplified breast cancer adult patients as adjuvant...